Portal de Periódicos da CAPES

LONG-TERM OUTCOME IN PATIENTS WITH pTxN+ ADENOCARCINOMA OF PROSTATE TREATED WITH RADICAL PROSTATECTOMY AND EARLY ANDROGEN ABLATION

1998; Lippincott Williams & Wilkins; Volume: 159; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(01)63917-x

1527-3792

Thomas Seay, Michael L. Blute, Horst Zincke,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyClinical Urology: Original Articles1 Feb 1998LONG-TERM OUTCOME IN PATIENTS WITH pTxN+ ADENOCARCINOMA OF PROSTATE TREATED WITH RADICAL PROSTATECTOMY AND EARLY ANDROGEN ABLATION Thomas M. Seay, Michael L. Blute, and Horst Zincke Thomas M. SeayThomas M. Seay , Michael L. BluteMichael L. Blute , and Horst ZinckeHorst Zincke View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63917-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed retrospectively the outcome after bilateral pelvic lymphadenectomy and radical prostatectomy for pathological pTxN+ adenocarcinoma of the prostate when treated with or without adjuvant androgen ablation therapy. Materials and Methods: A total of 790 men treated with radical prostatectomy for prostatic adenocarcinoma were found to have pTxN+ disease and treated further with or without androgen ablation therapy. Mean patient age was 64 years (range 40 to 79). Mean followup was 6.5 years, (range up to 25). Clinical stages were T2 or less in 60% of the cases, T3 in 38% and N+ in 2%. Gleason scores were 6 or less in 31% and 7 or greater in 69%. Deoxyribonucleic acid ploidy was diploid in 43%, tetraploid in 39% and aneuploid in 18%. Of the patients 96 (12%) received no androgen ablation therapy, with the remainder getting ablation therapy within 90 days of radical prostatectomy. Results: Of the patients 186 (24%) died, with 109 (14%) dying of prostatic anedocarcinoma. Overall (and cause specific) survival probabilities at 5, 10 and 15 years were 87 (91), 69 (79) and 39% (60%), respectively. Patients with diploid tumors had better cause specific survival than those with nondiploid tumors (p = 0.009). Patients with diploid tumors were less likely to have progression biochemically, locally or systematically than those with nondiploid tumors (p = 0.038). Androgen ablation therapy had no effect on cause specific survival in nondiploid patients. Diploid patients treated with androgen ablation therapy for up to 10 years had no improvement in disease specific survival compared to those with no androgen ablation therapy. However, cancer death was significantly reduced after 10 years (p <0.002). The local control rate of pTxN+ cases that receive radical prostatectomy and androgen ablation therapy at 15 years is virtually identical to that of stage pT2c cases at our institution (79 +/− 3.0 versus 80% +/− 3.5%, respectively). There were no deaths secondary to radical prostatectomy, and complications were within the experience of that seen in patients with localized disease. Conclusions: Radical prostatectomy with androgen ablation therapy is a viable option for patients with pTxN+ disease, particularly in view of excellent local control rates and low morbidity. Patients with diploid tumors have a more favorable outcome than those with nondiploid tumors when treated with androgen ablation therapy. References 1 : Cancer statistics, 1996. Ca Cancer J.. Clin.1996; 46: 5. Google Scholar 2 : Prostate specific antigen and transrectal ultrasound cause an early downward stage migration in prostate cancer which is not manifest in patients undergoing radical prostatectomy.. J. Urol.1993; 149: 347A. part 2, abstract 536. Google Scholar 3 : The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma.. J. Urol.1979; 121: 300. Link, Google Scholar 4 : Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases.. J. Urol.1976; 115: 89. Link, Google Scholar 5 : Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases.. J. Urol.1982; 128: 498. Link, Google Scholar 6 : Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer.. J. Urol.1992; 147: 1574. Link, Google Scholar 7 : Evaluation of the current incidence of nodal metastasis from prostate cancer.. J. Surg. Oncol.1993; 52: 269. Google Scholar 8 : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.. J. Urol.1994; 152: 1850. Link, Google Scholar 9 : New concepts in the treatment of stage D1 adenocarcinoma of the prostate.. Urol. Clin. N. Amer.1990; 17: 867. Google Scholar 10 : Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to 4, N1 to 3, M0D1).. J. Urol.1995; 154: 2118. Link, Google Scholar 11 : Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression.. J. Urol.1993; 150: 400. Link, Google Scholar 12 : Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma.. J. Urol.1982; 127: 935. Link, Google Scholar 13 : Impact of external irradiation on local symptoms and survival free of disease in patients with pelvic lymph node metastasis from adenocarcinoma of the prostate.. J. Urol.1984; 131: 705. Link, Google Scholar 14 : Radiation therapy for cancer of the prostate.. In: Management of Genito-urinary Cancer.. Edited by . Philadelphia: W. B. Saunders1988: 437. Google Scholar 15 : Treatment options for patients with stage D1 (T0-3, N1-2, M0) adenocarcinoma of prostate.. Urology.1987; 30: 307. Google Scholar 16 : The value of testosterone deprivation in stage D1 carcinoma of the prostate.. J. Urol.1988; 139: 1242. Link, Google Scholar 17 : Stage D1 prostate cancer: a nonrandomized comparison of conservative treatment options versus radical prostatectomy.. Cancer.1993; 71: 996. Google Scholar 18 : Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.. Urology.1994; 44: 719. Google Scholar 19 : The challenge of treating node-positive prostate cancer: an approach to resolving the questions.. Cancer.1993; 71: 1014. Google Scholar 20 : Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.. J. Urol.1994; 151: 1330. Link, Google Scholar 21 : Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors.. Cancer.1992; 70: 311. Google Scholar 22 : Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer.. Eur. Urol.1995; 27: 202. Google Scholar 23 : Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987.. J. Urol.1990; 144: 1425. Link, Google Scholar 24 : Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience.. Sem. Urol.1990; 8: 175. Google Scholar 25 : Prognosis of patients with stage D1 prostate cancinoma following radical prostatectomy with and without early endocrine therapy.. J. Urol.1990; 144: 700. Google Scholar 26 : Combined hormonal and radiation therapy for lymph node-positive prostate cancer.. Urology.1995; 46: 213. Google Scholar 27 : Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome.. Eur. Urol.1994; 25: 189. Google Scholar 28 : The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostate cancer.. Prostate.1984; 5: 1. Google Scholar 29 : Relationship between tumor size and the curability of metastatic prostate cancer by surgery alone or in combination with adjuvant chemotherapy.. J. Urol.1988; 139: 1119. Link, Google Scholar 30 : Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement.. Urology.1982; 19: 238. Google Scholar 31 : Extended experience with surgical treatment of stage D1 adenocarcinoma of the prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome.. Urology.1989; 33: 27. Google Scholar 32 : Observations on the surgical management of carcinoma of the prostate with limited regional nodal metastases.. Urology.1984; 24: 137. Google Scholar 33 : Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World.. J. Urol.1994; 12: 308. Google Scholar 34 : Prognostic significance of lymph nodal metastases in prostate cancer.. J. Urol.1989; 142: 332. Link, Google Scholar 35 : The effects of local and regional treatment on the metastatic outcome in prostate carcinoma with pelvic lymph node involvement.. Int. J. Rad. Oncol. Biol. Phys.1993; 28: 7. Google Scholar 36 : Radical prostatectomy in patients with clinical T2c, T3, and pathologic N+ adenocarcinoma of the prostate.. In: Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, June 22-24, 1994.. Edited by . : Scientific Communication International Ltd.1993: 237. Google Scholar Department of Urology, Mayo Clinic, Rochester, Minnesota.© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byEastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J, Eggener S, Horwitz E, Kane C, Kirkby E, Lin D, McBride S, Morgans A, Pierorazio P, Rodrigues G, Wong W and Boorjian S (2022) Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-UpJournal of Urology, VOL. 208, NO. 1, (19-25), Online publication date: 1-Jul-2022.DANESHMAND S, QUEK M, STEIN J, LIESKOVSKY G, CAI J, PINSKI J, SKINNER E and SKINNER D (2018) PROGNOSIS OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY: LONG-TERM RESULTSJournal of Urology, VOL. 172, NO. 6 Part 1, (2252-2255), Online publication date: 1-Dec-2004.ZWERGEL U, LEHMANN J, WULLICH B, SCHREIER U, REMBERGER K, ZWERGEL T and STOECKLE M (2018) Lymph Node Positive Prostate Cancer: Long-Term Survival Data After Radical ProstatectomyJournal of Urology, VOL. 171, NO. 3, (1128-1131), Online publication date: 1-Mar-2004.AKDUMAN B and CRAWFORD E (2018) The Management of High Risk Prostate CancerJournal of Urology, VOL. 169, NO. 6, (1993-1998), Online publication date: 1-Jun-2003.LAU W, BERGSTRALH E, BLUTE M, SLEZAK J and ZINCKE H (2018) RADICAL PROSTATECTOMY FOR PATHOLOGICAL GLEASON 8 OR GREATER PROSTATE CANCER: INFLUENCE OF CONCOMITANT PATHOLOGICAL VARIABLESJournal of Urology, VOL. 167, NO. 1, (117-122), Online publication date: 1-Jan-2002.ZINCKE H, LAU W, BERGSTRALH E and BLUTE M (2018) ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, VOL. 166, NO. 6, (2208-2215), Online publication date: 1-Dec-2001.WALSH P, DEWEESE T and EISENBERGER M (2018) A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENTJournal of Urology, VOL. 166, NO. 2, (508-516), Online publication date: 1-Aug-2001.MENG M and CARROLL P (2018) WHEN IS PELVIC LYMPH NODE DISSECTION NECESSARY BEFORE RADICAL PROSTATECTOMY? A DECISION ANALYSISJournal of Urology, VOL. 164, NO. 4, (1235-1240), Online publication date: 1-Oct-2000.BRINKER D, ROSS J, TRAN T, JONES D and EPSTEIN J (2018) CAN PLOIDY OF PROSTATE CARCINOMA DIAGNOSED ON NEEDLE BIOPSY PREDICT RADICAL PROSTATECTOMY STAGE AND GRADE?Journal of Urology, VOL. 162, NO. 6, (2036-2039), Online publication date: 1-Dec-1999.GHAVAMIAN R, BERGSTRALH E, BLUTE M, SLEZAK J and ZINCKE H (2018) RADICAL RETROPUBIC PROSTATECTOMY PLUS ORCHIECTOMY VERSUS ORCHIECTOMY ALONE FOR pTxN+ PROSTATE CANCER: A MATCHED COMPARISONJournal of Urology, VOL. 161, NO. 4, (1223-1228), Online publication date: 1-Apr-1999. Volume 159Issue 2February 1998Page: 357-364 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information Thomas M. Seay Current address: Wilford Hall Medical Center; Lackland Air Force Base, San Antonio, Texas 78236. More articles by this author Michael L. Blute More articles by this author Horst Zincke Requests for reprints: Department of Urology, Mayo Clinic, 200 First St., S.W., Rochester, Minnesota 55905. More articles by this author Expand All Advertisement PDF downloadLoading ...